Prescription dose in permanent seed prostate implants
Authors:
- Dwight E. HeronDHDwight E. Heron
- Krishna KomanduriKKKrishna Komanduri
- M. Saiful HuqMHM. Saiful Huq
- 18 July 2005
- journal article
- research article
- Published by Wiley in Medical Physics
- Vol. 32 (8) , 2496-2502
Abstract
Recently, seeds have been introduced for prostate permanent seed implants. This type of seed has a relatively short half‐life of 9.7 days and has its most prominent emitted photon energy peaks in the 29–34 keV region. Traditionally, 145 and 125 Gy have been prescribed for and seed prostate implants, respectively. Since both the half‐life and dosimetry characteristics of seed are quite different from those of and , the appropriate prescription dose for seed prostate implant may well be different. This study was designed to use a linear quadratic radiobiological model to determine an appropriate dose prescription scheme for permanent seed prostate implants. In this model, prostate edema was taken into consideration. Calculations were also performed for tumors of different doubling times and for other related radiobiological parameters of different values. As expected, the derived prescription dose values were dependent on type of tumors and types of edema. However, for prostate cancers in which tumor cells are relatively slow growing and are reported to have a mean potential doubling time of around 40 days, the appropriate prescription dose for permanent seed prostate implants was determined to be: if the experiences of seed implants were followed and if the experiences of seed implants were followed.Keywords
This publication has 20 references indexed in Scilit:
- Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculationsMedical Physics, 2004
- How low is the α/β ratio for prostate cancer?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- How low is the α/β ratio for prostate cancer?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Monte Carlo modeling of the transverse‐axis dose distribution of the Model 200 interstitial brachytherapy sourceMedical Physics, 2000
- Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 Interstitial Sources: Dosimetry and calibration changes: Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc SubcommitteeMedical Physics, 1999
- Timing of Computed Tomography–Based Postimplant Assessment Following Permanent Transperineal Prostate BrachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43Medical Physics, 1995
- Permanent implants using Au-198, Pd-103 and I-125: Radiobiological considerations based on the linear quadratic modelInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992
- Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic modelBritish Journal of Radiology, 1989
- The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapyBritish Journal of Radiology, 1985